How the Cannabis Lobby Finally Got Trump to Budge
Cannabis didn’t win Trump over with a single argument. It wore him down.
For more than a year, executives, advocates, pollsters and old friends circled one of the most famously sober presidents in modern history, pushing a narrow idea again and again: marijuana doesn’t belong in the same federal category as heroin.
By the time President Donald Trump signed his executive order to reclassify cannabis, the decision wasn’t sudden. It was the result of a coordinated campaign that blended old-fashioned relationships, modern political data and the slow normalization of an industry that Washington once refused to acknowledge, as reported by CNBC and Politico.
The pitch that finally landed
Trump’s move followed months of targeted outreach that reframed cannabis not as a cultural flashpoint, but as a medical and business issue. Industry insiders describe a strategy that leaned heavily on polling, personal appeals and regulatory language designed to resonate with a president who prides himself on being tough, transactional and unmoved by ideology.
“I’ve never been inundated by so many people as I have about” reclassifying marijuana, Trump said during the Oval Office signing ceremony.
That line matters. It tells you this wasn’t about one donor, one meeting or one check. It was about volume.
The people who kept calling
At the center of that pressure campaign were three very different figures.
One was Howard Kessler, a Palm Beach billionaire and longtime Trump confidant who has advocated for medical cannabis since surviving leukemia. Kessler didn’t come at the issue as a culture warrior. He came as a patient and a senior, pushing the case for CBD access and medical research. Trump shared videos from Kessler’s Commonwealth Project on social media months before the executive order.
During the signing, Health and Human Services Secretary Robert F. Kennedy Jr. acknowledged Kessler’s role: “We wouldn’t be here today” without him.
Another was Kim Rivers, CEO of Trulieve, who spent years positioning cannabis as a regulated, tested, medical product rather than a social statement. Rivers met with Trump multiple times, including in Florida and at the White House, pressing for reclassification and research, according to Politico.
“We haven’t necessarily been at the table in the past,” Rivers said in an interview. “Now we are.”
The third influence wasn’t a person in the room, but data. Polling conducted by Trump’s longtime pollster, Tony Fabrizio, showed overwhelming support for rescheduling, particularly among younger voters. Trump cited that polling repeatedly during the signing ceremony, signaling that public opinion had become impossible to ignore.
Yes, there was lobbying. Of course there was.
Campaign finance records and lobbying disclosures show cannabis companies and industry-backed political committees spent millions pushing their case in Washington in 2025, a theme echoed in coverage from outlets including the Washington Examiner. They hired lobbyists with Republican ties. They funded ads. They backed polling. They donated to political committees aligned with Trump.
None of this was hidden. None of it was illegal. And none of it is unique to cannabis.
Every major industry that wants policy movement in Washington does the same thing. What’s different here is that cannabis is finally being treated like one of them.
What this is — and what it isn’t
Reclassifying marijuana does not legalize it. It does not erase criminal records. It does not end federal prohibition or repair decades of harm.
But it does something important.
It forces the federal government to formally acknowledge what patients, doctors and researchers have said for years: cannabis has medical value and does not belong in Schedule I.
That shift opens doors to research, changes the math for operators crushed by punitive tax rules and signals that the era of total federal denial is ending, even if slowly.
The uncomfortable truth
This win didn’t come from protest alone. It came from access.
It came from relationships, polling decks, repeated conversations and strategic restraint. Cannabis advocates didn’t ask for everything. They asked for something achievable and kept asking until the answer changed.
That reality may make some people uneasy. Incremental reform often benefits institutions before individuals. Capital tends to move faster than justice.
But pretending this step is worse than nothing is dishonest.
The Door Isn’t Wide Open. But It’s Open.
Cannabis didn’t sell out to get here. It grew up.
It learned how Washington works, whether we like that system or not, and used the tools available to move the needle. Rescheduling is not the destination. It’s proof that the door is no longer locked.
The next question isn’t whether this step was imperfect.
It’s whether the industry, and the movement around it, knows how to keep pushing once the room finally opened.
Image: Shutterstock
<p>The post How the Cannabis Lobby Finally Got Trump to Budge first appeared on High Times.</p>
